In the latest data point for Q1'26, AbbVie (ABBV) reported an ROE of -10.37%, an ROA of 0.51%, and an ROIC of 2.03%. This represents a notable recovery from the preceding Q4'25, where ROE reached -55.54%, although profitability metrics remain significantly pressured compared to historical levels. Throughout the period from Q2'23 to Q1'26, the company's return metrics exhibited extreme volatility, particularly in ROE which swung from a peak of 90.56% in Q1'25 to a sharp decline of -512.57% in Q2'25. While ROA and ROIC remained relatively more stable, both experienced a significant dip in Q4'24 and Q3'25, reflecting periods of operational challenges or significant structural adjustments. The divergence between the highly volatile ROE and the more consistent ROA suggests substantial shifts in the company's equity base or leverage structure during these fiscal periods.